- Byung-Wook Kim, Jong Jae Park, Hee Seok Moon, Wan Sik Lee, Ki-Nam Shim, Gwang Ho Baik, Yun Jeong Lim, Hang Lak Lee, Young Hoon Youn, Jun Chul Park, In-Kyung Sung, Hyunsoo Chung, Jeong Seop Moon, Gwang Ha Kim, Su Jin Hong, Hyuk Soon Choi. The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study. Gut and Liver 2024;18:257

- Ye Zong, Cheng Lan, Xing Li, Weixing Chen, Honghui Chen, Aijun Liao, Side Liu, Chanyan Hu, Yongdong Wu, Shutian Zhang. Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study. Current Medical Research and Opinion 2024;40:1855

- Ting Jin, Wei Wu, Lei Zhang, Han Xuan, Haixiang Zhang, Li Zhong. The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials. Therap Adv Gastroenterol 2025;18

- Fumiaki Ishibashi, Sho Suzuki, Mizuki Nagai, Kentaro Mochida, Tetsuo Morishita. Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments. Gut and Liver 2023;17:684

- Yuichiro Noiri, Ryoko Nagata. Current status of gastric and oral infection/diseases caused by Helicobacter pylori. Oral Science International 2023;20:182

- Joseph Edwin Kanu, Jonathan Soldera. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis. World J Gastroenterol 2024;30:1213

- Joon Sung Kim, Weonjin Ko, Jun‐Won Chung, Tae Ho Kim. Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study. Helicobacter 2023;28

- Abdullah Shah, Omer Usman, Tafseer Zahra, Sandipkumar S Chaudhari, Gopi Sairam Reddy Mulaka, Rumaisa Masood, Saima Batool, Faraz Saleem. Efficacy and Safety of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors as Helicobacter pylori Eradication Therapy: A Meta-Analysis of Randomized Clinical Trials. 2023

- Zongchao Liu, Hengmin Xu, Weicheng You, Kaifeng Pan, Wenqing Li. Helicobacter pylori eradication for primary prevention of gastric cancer: progresses and challenges. Journal of the National Cancer Center 2024;4:299

- Ju Yup Lee. Helicobacter pylori. 2024.

- György Miklós Buzás, Péter Birinyi. Newer, Older, and Alternative Agents for the Eradication of Helicobacter pylori Infection: A Narrative Review. Antibiotics 2023;12:946

- Jin Lee. Role of Tegoprazan in Helicobacter pylori Eradication Therapy. Gut and Liver 2022;16:493

- Han-Ning Liu, Rui Wang, Yan Cao, Feng Xian, Xian-Jin Bi, Ding-Jian Wu, Bin Wang, Xing-Wei Wang, Chun-Hui Lan. Comparison of the Efficacy Between the Dual Therapy of Tegoprazan and the Quadruple Therapy of Tegoprazan: A Randomized Controlled Multicenter Study. Clin Transl Gastroenterol 2024;15:e1

- Jong Kyu Park. Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers. Korean J Helicobacter Up Gastrointest Res 2023;23:180

- Theodore Rokkas, Konstantinos Ekmektzoglou, Yaron Niv, David Y. Graham. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol 2024

- Chan Hyuk Park, Myung Jin Song, Byung Wook Jung, Jung Ho Park, Yoon Suk Jung. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. JPM 2022;12:1918

- Byung Wook Jung, Yun Jin Kim, Chan Hyuk Park. Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices. Helicobacter 2024;29

- Myung Jin Song, Byung Wook Jung, Chan Hyuk Park. Comprehensive Analysis of Factors Associated With Helicobacter pylori Eradication Therapy. Korean J Helicobacter Up Gastrointest Res 2024;24:157

- György Miklós Buzás. A káliumkompetitív savgátlók szerepe a felső emésztőtraktus savfüggő betegségeinek kezelésében. OH 2023;164:1967

- Byeong Yun Ahn, Soo-Jeong Cho. Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2023;23:174

- Yujing Du, Lixiu Yu, Bin Deng, Qinying Li, Junrui Hu, Linjie Li, Yusen Xu, Liangwei Song, Fang Xie, Yinghui Wang, Yuhao Chen, Chengxin Liu, Xuejia Zhai, Yongning Lu. Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial. Clin Drug Investig 2024;44:343

- Yoon Jin Choi. Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers. Korean J Gastroenterol 2022;80:247

- Ji Yoon Kim, Sang Gyun Kim, Soo-Jeong Cho. Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study. 2023;102:e36310

- Ji Hyun Kim, Sung Chul Park. What Is the Optimal Drug Regimen for Helicobacter pylori Eradication Therapy?. Korean J Helicobacter Up Gastrointest Res 2024;24:97

- Sung Eun Kim. Approach to Patients with Consecutive Helicobacter pylori Eradication Failure. Korean J Helicobacter Up Gastrointest Res 2023;23:15

- Jun-Hyung Cho.
Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line
Helicobacter pylori
eradication: a real-world evidence study
. Expert Review of Anti-infective Therapy 2024;22:793

- In Mo Yoon, Kang-Yon Kim, Kwan-Haeng Lee, Duk-Woo Yoo, Hojin Oh. Efficacy of Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric ulcers: Bayesian and frequentist Network Meta-analysis With Cross-inference Through a Quality management System. Current Therapeutic Research 2025:100776

- Jin Hee Noh. Current Status and Future Perspectives of Tegoprazan-Based Helicobacter pylori Eradication Therapy. Korean J Helicobacter Up Gastrointest Res 2024;24:100

- Yong Hwan Kwon, Seong Woo Jeon, Su Youn Nam, Dong Wook Lee, Ji Hey Park, Hui Jin Bae. Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication. Korean J Intern Med 2023;38:493

- Qingzhou Kong, Iqtida Ahmed Mirza, Xiaoqian Zhang, Xiaohui Song, Xiaowei Li, Qiumei Zhang, Lidong Xu, Yuting Guo, Yanan Yu, Xiuli Zuo, Yanqing Li, Yueyue Li. Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial. Helicobacter 2024;29

- 岚 卿. Progress of Potassium-Competitive Acid Blocker Tegoprazan in the Treatment of Acid-Related Diseases. ACM 2024;14:117

- Hyun Ho Choi. Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?. Gut and Liver 2023;17:668

- Pengtuo Xiao, Changfeng Li, Yuanda Liu, Yan Gao, Xiaojing Liang, Chang Liu, Wei Yang. The role of metal ions in the occurrence, progression, drug resistance, and biological characteristics of gastric cancer. Front. Pharmacol. 2024;15

- Chan Hyuk Park. Helicobacter Infection in Clinical Practice. 2024.

- Jieun Lee, Jeong-Ju Yoo. The current state of graphical abstracts and how to create good graphical abstracts. Sci Ed 2023;10:19

- Younghee Choe. Antibiotic Resistance and Helicobacter pylori Eradication Therapy. Korean J Helicobacter Up Gastrointest Res 2023;23:218

- Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung. Comparative efficacy of tegoprazan versus esomeprazole/sodium bicarbonate for the treatment of Helicobacter pylori infection. Clin Transl Gastroenterol 2023

- Hye Kyung Jeon, Gwang Ha Kim, Yong-Il Cheon, Sung-Chan Shin, Byung Joo Lee. Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study. JCM 2023;12:6116

- Seokin Kang, Nam-Hoon Kim, Seokhyeon Jeong, Jong Wook Kim, Jung Rock Moon, Yoon Suk Lee, Jun Hyuk Son. Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2024;24:168

- Seong Hyun Cho, Moon Sik Park, Seon-Young Park, Dong Hyun Kim, Hye-Su You, Hyun-Soo Kim. Effectiveness of 7-day triple therapy with half-dose clarithromycin for the eradication of Helicobacter pylori without the A2143G and A2142G point mutations of the 23S rRNA gene in a high clarithromycin resistance area. Front. Med. 2023;10

- Yutong Jiang, Rongrong Zhang, Yuxuan Fang, Ruixia Zhao, Yu Fu, Pingping Ren, Qingqing Zhan, Mingyi Shao. P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis. Therap Adv Gastroenterol 2024;17

- Mengling Ouyang, Shupeng Zou, Qian Cheng, Xuan Shi, Minghui Sun. Comparative Efficacy and Safety of Potassium‐Competitive Acid Blockers and Proton Pump Inhibitors for First‐Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta‐Analysis. Helicobacter 2024;29

- E. A. Ortenberg, M. V. Lyapina, E. F. Dorodnyeva. Competitive proton pump inhibitors - status and Prospects of use. jour 2023:86

- Byung Wook Jung, Chan Hyuk Park, Yoon Suk Jung. Efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for Helicobacter pylori infection: Real‐world evidence. J of Gastro and Hepatol 2024;39:2409

- Ji Yong Ahn. Helicobacter Infection in Clinical Practice. 2024.

- Jin Hee Noh, Kee Don Choi. Vonoprazan-based Dual and Triple Therapy for Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2023;23:228

- Caio Constantini Rosa, Jessé Rodrigues de Moraes. Tratamento Das Infecções Por Helicobacter Pylori: Revisão De Ensaios Clínicos. jmrr 2022;1:e021

- Hyun Jung Lee, Ji Wook Moon, Seong-Joon Koh, Jong Pil Im, Byeong Gwan Kim, Joo Sung Kim. Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy. Sci Rep 2024;14

- Katarina Jankovic, Ian M. Gralnek, Halim Awadie. Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers. 2025;76:143

- Carmelo Scarpignato, Richard H. Hunt. Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. Curr Gastroenterol Rep 2024;26:273

- Jun-Hyung Cho, So-Young Jin, Suyeon Park.
Comparison of tegoprazan and proton pump inhibitors for first-line
Helicobacter pylori
eradication: a systematic review with meta-analysis
. Expert Review of Anti-infective Therapy 2025:1

- Zhuodu Wei, Hyeon-Cheol Jeong, Min-Gul Kim, Kwang-Hee Shin. Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model. Pharmaceuticals 2023;16:360

- Yoon Suk Jung, Sunyong Kim, Hyun-Young Kim, Seung Jae Noh, Jung Ho Park, Chong Il Sohn, Chan Hyuk Park. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study. Gut and Liver 2023;17:711

- Jung Won Lee, Nayoung Kim, Jongchan Lee, So Young Jo, Dong Ho Lee. Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study. Helicobacter 2024;29

- Nicole T. Cerf, Gerardo Zerbetto de Palma, Natalya U. Fedosova, Claudia V. Filomatori, Rolando C. Rossi, Santiago E. Faraj, Mónica R. Montes. How ligands modulate the gastric H,K-ATPase activity and its inhibition by tegoprazan. Journal of Biological Chemistry 2024;300:107986
